Apontis Pharma AG (FRA:APPH) Financial Strength: 0 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:APPH Apontis Pharma AG FRA:APPH
17 GF Score
Price €11.00
GF Value €10.46
! 7 Warning Signs
View Full Analysis

What is Apontis Pharma AG Financial Strength?

Apontis Pharma AG has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Apontis Pharma AG has no long-term debt (1). Apontis Pharma AG's debt to revenue ratio for the quarter that ended in Jun. 2025 was 0.00. As of today, Apontis Pharma AG's Altman Z-Score is 5.44.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Apontis Pharma AG  (FRA:APPH) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Apontis Pharma AG has the Financial Strength Rank of 0.

Apontis Pharma AG Financial Strength Related Terms

FRA:APPH vs ZTS, UTHR, NBIX: Financial Strength Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apontis Pharma AG Financial Strength vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Financial Strength distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's Financial Strength falls into.


FRA:APPH
17GF Score
Apontis Pharma AG FRA:APPH
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apontis Pharma AG Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Apontis Pharma AG's Interest Expense for the months ended in Jun. 2025 was €0.00 Mil. Its Operating Income for the months ended in Jun. 2025 was €0.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was €0.00 Mil.

Apontis Pharma AG's Interest Coverage for the quarter that ended in Jun. 2025 is

Apontis Pharma AG had no long-term debt (1).

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Apontis Pharma AG's Debt to Revenue Ratio for the quarter that ended in Jun. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 52.066
=0.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Apontis Pharma AG has a Z-score of 5.44, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 5.44 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?

Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued. The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.

Key valuation signals for FRA:APPH:

  • Financial Strength: 0
  • GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
  • GF Score™: 17/100 with 7 warning signs

No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apontis Pharma AG Business Description

Address Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score

Get the complete analysis for FRA:APPH

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price
€10.46
GF Value